The collaboration will use Tempus tests, like the Tempus xT broad-panel genomic sequencing assay that is designed to detect actionable alterations by sequencing tumor samples with matched normal saliva or blood samples. Eli Lilly will help to expand access to genomic testing by removing cost as a barrier for NSCLC patients to receive molecular profiling. In patients for whom tissue is unavailable or is not sufficient to conduct broad-based tissue testing, Tempus' xF liquid biopsy is available as an alternative. Physicians will also be able to order select immunohistochemistry staining, the firms said.

Lilly establishes Institute for Genetic Medicine, invests in Boston Seaport site
Eli Lilly has launched the Lilly Institute for Genetic Medicine and invested approximately $700 million to establish a state-of-the-art facility at a...

Eli Lilly's bebtelovimab receives EUA for mild-to-moderate COVID-19
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Eli Lilly's antibody bebtelovimab, which demonstrates neutralization...

Lilly, Regor Therapeutics Group enter into strategic collaboration
Eli Lilly and Regor Therapeutics Group have entered into a multiyear research collaboration and licensing agreement to discover, develop, and commercialize...

Startup Mozart targets autoimmune, inflammatory diseases
Biopharmaceutical startup Mozart Therapeutics has launched with a focus on developing therapeutics for autoimmune and inflammatory diseases.

Tempus unveils cloud-based data and analytics platform
Artificial intelligence (AI) developer Tempus announced the launch of Lens, a cloud-based data and analytics platform.